Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- JPA’s Abe Says Link between Pricing Premium and New Drug Development Blurry
April 13, 2015
- PAFSC’s Second Committee to Review PegIntron, Talion on April 24
April 13, 2015
- Consumer Affairs Agency Warns Public of Adverse Reaction Risks of OTC Drugs
April 10, 2015
- Set Ceiling for Health Coverage of OTC-Like Drugs: Govt Panel
April 9, 2015
- Chuikyo to Focus Sights on Unused Medication, Long-Term Prescriptions in Discussions
April 9, 2015
- Orphan Designation System Should Be Adjusted for Factors Including Company Scale: Report
April 8, 2015
- Most Cancer Drugs Would Cost Over 1 Million Yen a Month under Patient-Initiated Mixed Care: NCC
April 7, 2015
- MEXT Secures FY2015 Budgets for Generic Promotion Subsidy Project
April 7, 2015
- Overlapping of All-Case Surveys and EPPV Inefficient: Mr Uda of FPMAJ
April 7, 2015
- PMDA Reviewing Plavix for Risk of Acute Generalized Exanthematous Pustulosis
April 6, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 23 - April 5
April 6, 2015
- Govt, Pharma Leaders to Hold Policy Dialogue on April 13
April 6, 2015
- Abe Pins Hopes of Innovation on AMED
April 6, 2015
- MHLW to Accept Applications for “Sakigake” Designation from May 8
April 6, 2015
- MHLW Orders Revision of Package Inserts for Cetuximab, Panitumumab
April 3, 2015
- MHLW Requires Municipalities to Compile Generic Promotion Plans for Welfare Recipients
April 3, 2015
- AMED Inaugurated with Diverse Talents as Unit Heads
April 2, 2015
- MHLW Notifies of New Criteria for Orphan Drug Designation
April 2, 2015
- MHLW Notifications Prod Generic Use under High-Cost Healthcare Benefit System
April 2, 2015
- PMDA Sets Up New Unit to Promote Medical Database Project
April 1, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…